Adzhubei, I. A., Schmidt, S., Peshkin, L., Ramensky, V. E., Gerasimova, A., Bork, P., . . . Sunyaev, S. R. (2010). A method and server for predicting damaging missense mutations. Nat Methods, 7(4), 249-249.
Arici, M., & Özhan, G. (2017). The genetic profiles of CYP1A1, CYP1A2 and CYP2E1 enzymes as susceptibility factor in xenobiotic toxicity in Turkish population. Saudi Pharmaceutical Journal, 25(2), 294-297.
Banas, J. S., Jr. (1992). Effects of inhibitors of angiotensin-converting enzyme on regional hemodynamics. Am J Cardiol, 69(10), 40c-45c.
Delozier, T. C., Kissling, G. E., Coulter, S. J., Dai, D., Foley, J. F., Bradbury, J. A., . . . Goldstein, J. A. (2007). Detection of Human CYP2C8, CYP2C9 and CYP2J2 in Cardiovascular Tissues. Drug Metabolism & Disposition the Biological Fate of Chemicals, 35(4), 682.
Dreisbach, A. W., Japa, S., Sigel, A., Parenti, M. B., Hess, A. E., Srinouanprachanh, S. L., . . . Lertora, J. J. (2005). The Prevalence of CYP2C8, 2C9, 2J2, and soluble epoxide hydrolase polymorphisms in African Americans with hypertension. Am J Hypertens, 18(10), 1276-1281. doi:10.1016/j.amjhyper.2005.04.019
Flanagan, S. E., Patch, A. M., & Ellard, S. (2010). Using SIFT and PolyPhen to predict loss-of-function and gain-of-function mutations. Genetic Testing & Molecular Biomarkers, 14(4), 533-537.
Fohner, A., Muzquiz, L. A. I., Austin, M. A., Gaedigk, A., Gordon, A., Thornton, T., . . . Howlett, K. (2013). Pharmacogenetics in American Indian Populations: Analysis of CYP2D6, CYP3A4, CYP3A5, and CYP2C9 in the Confederated Salish and Kootenai Tribes. Pharmacogenetics & Genomics, 23(8), 403-414.
Gervasini, G., Vizcaino, S., Carrillo, J. A., Caballero, M. J., & Benitez, J. (2006). The effect of CYP2J2, CYP3A4, CYP3A5 and the MDR1 polymorphisms and gender on the urinary excretion of the metabolites of the H-receptor antihistamine ebastine: a pilot study. Br J Clin Pharmacol, 62(2), 177-186. doi:10.1111/j.1365-2125.2006.02578.x
Hoffmann, M. M., Bugert, P., Seelhorst, U., Wellnitz, B., Winkelmann, B. R., Boehm, B. O., & Marz, W. (2007). The -50G>T polymorphism in the promoter of the CYP2J2 gene in coronary heart disease: the Ludwigshafen Risk and Cardiovascular Health study. Clin Chem, 53(3), 539-540. doi:10.1373/clinchem.2006.084756
King, L. M., Gainer, J. V., David, G. L., Dai, D., Goldstein, J. A., Brown, N. J., & Zeldin, D. C. (2005). Single nucleotide polymorphisms in the CYP2J2 and CYP2C8 genes and the risk of hypertension. Pharmacogenet Genomics, 15(1), 7-13.
King, L. M., Ma, J., Srettabunjong, S., Graves, J., Bradbury, J. A., Li, L., . . . Zeldin, D. C. (2002). Cloning of CYP2J2 gene and identification of functional polymorphisms. Molecular Pharmacology, 61(4), 840.
Korytina, G., Kochetova, O., Akhmadishina, L., Viktorova, E., & Victorova, T. (2012). Polymorphisms of cytochrome p450 genes in three ethnic groups from Russia. Balkan Med J, 29(3), 252-260. doi:10.5152/balkanmedj.2012.039
Kumar, P., Henikoff, S., & Ng, P. C. (2009). Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc, 4(7), 1073-1081. doi:10.1038/nprot.2009.86
Lai, S. W. S., Lopes, R. M., Doherty, E., Prosser, D. O., Tang, R., & Love, D. R. (2015). Analysis of BRCA gene missense mutations. 2(1).
Lee, S. S., Jeong, H. E., Liu, K. H., Ryu, J. Y., Moon, T., Yoon, C. N., . . . Shin, J. G. (2005a). Identification and functional characterization of novel CYP2J2 variants: G312R variant causes loss of enzyme catalytic activity. Pharmacogenet Genomics, 15(2), 105-113.
Lee, S. S., Jeong, H. E., Liu, K. H., Ryu, J. Y., Moon, T., Yoon, C. N., . . . Shin, J. G. (2005b). Identification and functional characterization of novel CYP2J2 variants: G312R variant causes loss of enzyme catalytic activity. Pharmacogenet Genomics, 15(2), 105-113.
Li, Q., Zhao, J. H., Ma, P. J., Su, L. L., Tao, S. B., & Ji, S. B. (2015). Association of CYP2J2 gene polymorphisms with ischemic stroke. International Journal of Clinical & Experimental Medicine, 8(5), 8163.
Liu, P. Y., Li, Y. H., Chao, T. H., Wu, H. L., Lin, L. J., Tsai, L. M., & Chen, J. H. (2007). Synergistic effect of cytochrome P450 epoxygenase CYP2J2*7 polymorphism with smoking on the onset of premature myocardial infarction. Atherosclerosis, 195(1), 199-206. doi:10.1016/j.atherosclerosis.2006.11.001
Liu, X., Shen, Q., Li, J., Li, S., Luo, C., Zhu, W., . . . Jiang, H. (2013). In silico prediction of cytochrome P450-mediated site of metabolism (SOM). Protein & Peptide Letters, 20(3), 279-289.
Shah, I. M., & Breslin, C. J. (2010). Pharmacogenetics of Cytochrome P450 2D6: A Translational Medicine Perspective. Paper presented at the Open Conference Journal.
Spiecker, M., Darius, H., Hankeln, T., Soufi, M., Sattler, A. M., Schaefer, J. R., . . . Lindpaintner, K. (2004). Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2. Circulation, 110(15), 2132.
Takeshita, H., Tsubota, E., Takatsuka, H., Kunito, T., & Fujihara, J. (2008). Cytochrome P450 2J2*7 polymorphisms in Japanese, Mongolians and Ovambos. Cell Biochem Funct, 26(7), 813-816. doi:10.1002/cbf.1512
Wang, H., Jiang, Y., Liu, Y., Lin, C., Cheng, G., Chen, X., . . . He, F. (2006). CYP2J2*7 single nucleotide polymorphism in a Chinese population. Clin Chim Acta, 365(1-2), 125-128. doi:10.1016/j.cca.2005.08.007
Wu, J., Li, Y., & Jiang, R. (2014). Integrating multiple genomic data to predict disease-causing nonsynonymous single nucleotide variants in exome sequencing studies. PLoS genetics, 10(3), e1004237.
Wu, S., Moomaw, C. R., Tomer, K. B., Falck, J. R., & Zeldin, D. C. (1996). Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. Journal of Biological Chemistry, 271(7), 3460.
Wu, S. N., Zhang, Y., Gardner, C. O., Chen, Q., Li, Y., Wang, G. L., . . . Zhu, D. L. (2007). Evidence for association of polymorphisms in CYP2J2 and susceptibility to essential hypertension. Annals of Human Genetics, 71(4), 519–525.
Xu, S., & Li, J. (2008). A Genome-wide Analysis of Admixture in Uyghurs and a High-Density Admixture Map for Disease-Gene Discovery. American Journal of Human Genetics, 83(3), 322.
Zhang, C., Chen, W., Li, Q., Shi, X., Xia, R., Zhang, N., . . . Yuan, D. Genetic polymorphism analysis of CYP2J2 drug-metabolizing enzyme in a Chinese Zhuang population.
Zhang, C., Cheng, Y., Dai, R., Zhang, X., Li, J., Zhu, X., . . . Yuan, D. Polymorphisms of drug-metabolizing enzyme CYP2J2 in Wa population from Yunnan Province of China.